KICVentures Will Exhibit Portfolio Companies, AxioMed, NanoFUSE and SpineFrontier at AANS Annual Meeting

Tuesday, April 16, 2019 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

KICVentures will exhibit its portfolio companies, AxioMed, NanoFUSE, and SpineFrontier at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, CA on April 13-17th, 2019 at Booth #2106.

MALDEN, Mass., April 15, 2019 /PRNewswire-PRWeb/ -- KICVentures will exhibit its portfolio companies, AxioMed,

NanoFUSE, and SpineFrontier at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, CA on April 13-17th, 2019 at Booth #2106.

"AANS is a great opportunity for us to introduce innovative, clinically-proven technology that surgeons might not have the opportunity to learn about otherwise," said Professor Kingsley R. Chin, M.D., the Founder and CEO of KICVentures. "What's so amazing is that Dr. Edward C. Benzel is one of AANS's honored guests and was also one of the initial three Founders of AxioMed before it was acquired by KICVentures, so it's appropriate that the AxioMed Freedom Disc will be on display for attendees to learn about."

Dr. Chin continued, "With the recent renewal of the CE Mark on the AxioMed FreedomŪ Cervical Disc, the disc's popularity continues to grow overseas — across Europe, Asia, and Australia. We are also seeing strong NanoFUSE adoption internationally — all the way to New Zealand. KICVentures believes that its portfolio companies NanoFUSE, AxioMed, and SpineFrontier will continue to disrupt spine surgery internationally. In 2019 KIC has already raised over $10 million in growth capital including international investors and surgeons."

NanoFUSE Biologics will be featured at an event by keynote speaker Professor Fassil Mesfin, M.D., Dr. Mesfin will present on "How NanoFUSE Bioactive Glass is Replacing Human Tissue for Spinal Fusion and Bone Healing" and on "Revolutionizing Percutaneous Pedicle Screws in the Era of Robotics." The event will take place on the evening of Monday, April 15th from 5:30-6:30 pm at the Hilton San Diego Gaslamp Quarter. If interested in attending, please contact Rosa Martinez at 1-239-961-6900.

Representatives from KICVentures will be present at the event to answer questions about its technologies and to talk about investment opportunities.

About KICVentures

KICVentures is a private investment, holding company founded by Harvard-trained, Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed, NanoFUSE, and SpineFrontier. KICVentures is headquartered in Boston, MA.

About SpineFrontier

SpineFrontier is a medical device technology company founded in 2006 that designs and develops proprietary, best-in-class implants and instruments for spine surgery based on the trademarked Less Exposure Surgery (LES (TM)) philosophy. SpineFrontier is a KICVentures' portfolio company and the leader in LES (TM) technologies.

About NanoFUSE Biologics

NanoFUSE is the synergistic blend of osteoinductive DBM combined with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in orthopedic surgery. NanoFUSE Biologics is a KICVentures portfolio company and is distributed by SpineFrontier.

About AxioMed

AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented, viscoelastic-polymer technology, AxioMed has developed the next generation of artificial discs. AxioMed completed its U.S. IDE for the Lumbar Disc with over five years of clinical follow-up.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store